<DOC>
	<DOCNO>NCT00293748</DOCNO>
	<brief_summary>This study determine drug Atorvastatin ( Lipitor ) change genetic material find blood cell people vascular ( blood vessel ) disease . Vascular disease affect blood flow body lead heart attack stroke . Information gain study could use develop reliable blood test predict risk heart attack stroke . People 21 old two risk factor develop vascular disease eligible study . Candidates screen medical history , physical examination , electrocardiogram , ultrasound carotid ( neck ) artery , blood test , check blood pressure heart rate . Participants randomly assign one four treatment group . Three group receive Lipitor dose either 10 , 20 40 milligram ; fourth group receive placebo . All take study drug 3 month . In addition , undergo follow test procedure : Study Phase I ( Months 2-4 ) Participants group see month NIH Clinical Center blood test monitor drug side effect . Study Phase 2 ( Months 5-10 ) - Placebo group : Participants give 40 mg Lipitor 3 month ( month 5-7 ) see physician month time . Blood draw 7-month visit participant refer back physician . During month 8 , 9 10 , participant call month check health . Participation end tenth month . - Lipitor group : Participants refer back physicians month 5 6 call month . During month 7 , return clinic follow-up evaluation blood test . Participation end seventh month .</brief_summary>
	<brief_title>Effect Atorvastatin ( Lipitor ) Gene Expression People With Vascular Disease</brief_title>
	<detailed_description>Background : Atherosclerosis consequence - coronary heart disease stroke - principal cause mortality develop country . Being able accurately predict individual 's risk vascular disease need preventive strategy measure effectiveness thereof . Current risk assessment tool imperfect best . It possible information gene expression profile peripheral white blood cell may add predictive information vascular risk . We previously identify panel 78 gene peripheral blood correlate individual 's future risk stroke . We hypothesize gene expression white blood cell modify intervention show reduce vascular risk via anti-inflammatory mechanism : 3-hydroxy-3-methylglutaryl coenzyme A ( HMGCoA ) reductase inhibitor class lipid lower drug , know `` statin '' . The vascular protective effect statins appear due part immune modulation dose-dependent . Statin administration show modulate gene expression peripheral blood mononuclear cell vitro . Objectives : Overall : To determine atorvastatin modulates gene expression peripheral blood mononuclear cell dose dependent manner cohort subject risk vascular disease . Specific : To determine : ( 1 ) Inflammatory gene specifically temporarily modify atrovastatin dose dependent manner ; ( 2 ) A previously define panel 78 gene include among gene modify atorvastatin ; ( 3 ) Gene expression change correlate degree gene expression modulation atorvastatin degree lipid lower inflammatory parameter high sensitivity C-reactive protein . Study Design : Dose-response randomized , blind study atorvastatin treatment 120 volunteer subject least two conventional vascular risk factor currently take statin . In first primary phase study , subject administer atorvastatin blind fashion one four dos ( 0mg , 10mg , 20mg 40mg ) period three month . Block randomization stratify age risk factor status . In second validation phase study , subject randomize 0mg atorvastatin phase 1 receive 40mg atorvastatin 3 month period . The remain subject randomize study drug phase II study . Lipid profile , liver function test muscle enzymes measure prior enrollment , treatment phase study . Gene expression profile peripheral blood measure use Affymetrix microarrays pre treatment end phase I II . Outcome measure : ( 1 ) Gene change induce statin treatment dosage time ; ( 2 ) Accuracy vascular gene panel define gene expression change induce statin treatment ; ( 3 ) Correlations gene expression change conventional vascular risk factor , change lipid inflammatory marker determination best vascular risk prediction paradigm .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>INCLUSION CRITERIA : Age 21 old Not take statin lipidlowering drug history statin use Two risk factor list : Age ( men great equal 45 year , woman great equal 55 year ) Hypertension ( BP great equal 140/90 antihypertensive medication ) Cigarette smoke Coronary heart disease equivalent ( include diabetes mellitus , abdominal aortic aneurysm , peripheral vascular disease , carotid artery disease ) Prior stroke transient ischemic attack Family history premature coronary heart disease ( CHD ) : CHD male first degree relative less 55 year CHD female first degree relative less 65 year Total cholesterol great equal 240mg/dL and/or LDL cholesterol great equal 160 mg/dL Low HDL cholesterol ( le 40 mg/dL ) Note : A high HDL cholesterol ( great 60 mg/dL ) count negative risk factor : presence remove one risk factor total count . EXCLUSION CRITERIA Current past history statin use Assessed need immediate statin treatment subject 's primary care physician Current use investigational drug part another research protocol Chronic active liver disease Chronic active muscle disease Alcohol abuse Prior myocardial infarct Heart failure Uncontrolled arrhythmias Any clinically important hematological biochemical abnormality routine screen Recent history cancer Pregnant woman breastfeed woman Concomitant use follow medication , include drug strongly inhibit CYP3A54 : nicotinic acid , gemfibrozil , clofibrate , fenofibrate , verapamil , mibefradil , cyclcosporin , nefazodone , fluoxetine , paroxetine , ketoconazole , itraconazole , cimetadine , clarithromycin , erythromycin , protease inhibitor , NSAIDs , celebrex</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 15, 2008</verification_date>
	<keyword>Genomics</keyword>
	<keyword>Statins</keyword>
	<keyword>Coronary Heart Disease</keyword>
	<keyword>Stroke</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Gene Expression</keyword>
	<keyword>Vascular Risk</keyword>
	<keyword>Peripheral Blood Mononuclear Cells</keyword>
	<keyword>Atorvastatin</keyword>
	<keyword>Vascular Disease</keyword>
	<keyword>Vascular Disease Risk</keyword>
</DOC>